Oxford Biomedica H2 Earnings Call Highlights

1 week ago 4

MarketBeat

Thu, March 26, 2026 astatine 10:08 AM CDT 8 min read

Oxford Biomedica logo

Oxford Biomedica reported 2025 gross up 33% astatine changeless currency to GBP 170.9m and a instrumentality to operating EBITDA profitability astatine GBP 8.1m (underlying GBP 3.3m excluding one-offs), with backlog and contracted orders rising to GBP 204m and GBP 224m and year-end currency of GBP 96.9m.
The institution completed an acquisition of an FDA‑approved commercialized viral vector installation successful Durham, North Carolina, adding integrated drug‑substance and fill‑and‑finish capableness (two GMP suites and 1 capable line) to accelerate U.S. commercialized AAV manufacturing and section supply‑chain resilience.
For 2026 absorption reiterates gross guidance of GBP 220–240m (about 60% contracted, >80% including risk‑adjusted pipeline), expects H1 EBITDA nonaccomplishment and H2 double‑digit margins with ~10% full‑year operating EBITDA, and highlights a pipeline displacement toward AAV and later‑stage programs.
Interested successful Oxford Biomedica plc? Here are 5 stocks we similar better.

Oxford Biomedica (LON:OXB) outlined a twelvemonth of gross growth, a instrumentality to operating EBITDA profitability, and continued enlargement of its planetary viral vector CDMO web during its preliminary full-year 2025 results call. Management emphasized that 2025 reflected “sustained commercialized momentum and disciplined execution,” supported by rising request crossed vector types and much lawsuit programs advancing toward late-stage and commercialized manufacturing.

Chief Executive Officer Dr. Frank Mathias said 2025 gross accrued 33% astatine changeless currency to GBP 170.9 million, representing astir a 90% summation from astir GBP 90 cardinal successful 2023. He besides highlighted the company’s increasing gross visibility, with backlog up 36% to GBP 204 million and contracted lawsuit orders rising 20% to GBP 224 million, which absorption said supports visibility into 2026 and aboriginal 2027.

→ Active ETFs Surge Past Passive, and These Are successful the Lead

The institution reported its archetypal afloat twelvemonth of operating EBITDA profitability since its strategical refocus 3 years ago. Operating EBITDA was GBP 8.1 million astatine changeless currency, compared with an operating EBITDA nonaccomplishment of GBP 15.3 million successful 2024. The radical ended 2025 with GBP 96.9 million successful cash.

Management besides pointed to equilibrium expanse actions during the year, including a GBP 60 million fundraising and a caller indebtedness installation from Oaktree, described arsenic providing flexibility to put successful capableness and capabilities.

→ Macy’s Beats Expectations Again, But Guidance Spooks Investors

A large strategical milestone successful 2025 was the acquisition of an FDA-approved commercial-scale viral vector manufacturing installation successful Durham, North Carolina. Mathias said the tract includes integrated cause substance and fill-and-finish capabilities and was positioned arsenic a “more capital-efficient” way to grow U.S. manufacturing than gathering a caller facility. He added that localizing proviso chains successful the U.S. offers taxation incentives and tin assistance negociate risks specified arsenic tariffs and export controls.

Read Entire Article